ADMA Biologics (NASDAQ:ADMA) will post its quarterly earnings results on Thursday, February 22nd. Analysts expect ADMA Biologics to post earnings of ($0.33) per share for the quarter.
ADMA Biologics (ADMA) opened at $4.02 on Thursday. The firm has a market capitalization of $98.79, a PE ratio of -4.90 and a beta of 2.58. The company has a quick ratio of 1.35, a current ratio of 2.36 and a debt-to-equity ratio of 2.26. ADMA Biologics has a one year low of $2.01 and a one year high of $5.44.
A number of equities analysts have weighed in on the company. Maxim Group restated a “buy” rating and issued a $8.00 target price (down from $13.00) on shares of ADMA Biologics in a research note on Monday, December 11th. Raymond James Financial upgraded ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research report on Tuesday, November 14th.
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.